Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says
November 6, 2015 8:17 AM ESTRoth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying their conditional-approval thesis remains unchanged.
Chattopadhyay commented, "A new therapy is not considered available therapy if granted accelerated approval based on a surrogate or... More
Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval
November 6, 2015 6:53 AM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they maintain high conviction in Eteplirsen approval.
Messer commented, "SRPT shares have pulled back from recent highs due to concerns that etelpirsen's later than expected... More
Trading Radar for 11/5: Disney (DIS), Celgene (CELG), SeaWorld (SEAS), Sprouts (SFM), CyberArk (CYBR) Report
November 4, 2015 3:11 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
A.M. Castle & Co. (NYSE: CAS) - no Street consensus
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus EPS $0.11
AES Corp (NYSE: AES) - consensus EPS $0.38
ANSYS... More
